Upgrade to SI Premium - Free Trial

Allergan (AGN) Phase 3 of Rapastinel as Adjunctive Treatment of MDD Did Not Meet Key Endpoints

March 6, 2019 4:19 PM
Allergan plc (NYSE: AGN) today announced topline results from three pivotal studies of rapastinel as an adjunctive treatment of Major ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Hot Corp. News Hot FDA News

Next Articles